Fluciclovine PET for Prostate Cancer

Not yet recruiting at 3 trial locations

Overseen By Lauren Dean

Age: 18+

Sex: Male

Trial Phase: Phase 4

Sponsor: Blue Earth Diagnostics

Must not be taking: Supplements, Herbal medications

Disqualifiers: Metastatic castrate resistant prostate cancer, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Prior Safety Data This treatment has passed at least one previous human trial

Compensation: Varies

Number of Visits: 1

What You Need to Know Before You Apply

What is the purpose of this trial?

The impact of fluciclovine (18F) PET on the management of participants with prostate cancer following negative or equivocal PSMA PET Imaging at the time of biochemical recurrence

Who Is on the Research Team?

Nadine Mallak, MD

Principal Investigator

Oregon Health and Science University

Are You a Good Fit for This Trial?

Inclusion Criteria

I am a male and at least 18 years old.

6. Ability of the participants to comply with planned study procedures

5. Participants must provide written informed consent before any study-specific procedures or interventions are performed.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Imaging

Participants receive a single intravenous administration of fluciclovine (18F) for PET Scan

1 day

1 visit (in-person)

Follow-up

Participants are monitored for changes in management following the imaging procedure

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

• Fluciclovine (18F)

How Is the Trial Designed?

Group I: Patients Single intravenous administration of fluciclovine (18F) for PET Scan Experimental Treatment 1 Intervention

Patients Single intravenous administration of fluciclovine (18F) for PET Scan

Who Is Running the Clinical Trial?

Blue Earth Diagnostics

Lead Sponsor

Trials

43

Recruited

3,100+